Gastroenterology Research and Practice / 2009 / Article / Tab 5 / Research Article
Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population Table 5 Allelic odds ratios and 95% confidence
intervals for comparison of TNFRSF1B variants with IBD status in New Zealand
IBD patients and Caucasians.
Allelic odds ratios and 95% Allelic odds ratios and 95% Allelic odds ratios and 95% confidence intervals for comparison of confidence intervals for comparison of confidence intervals for comparison of TNFRSF1_B1061622 TNFRSF1B_1061624 TNFRSF1B_3397 Crohns disease Ulcerative colitis Crohns disease Ulcerative colitis Crohns disease Ulcerative colitis OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI Female 1.20
1.38
1.10
1.00
0.85
0.96
Male 1.05
1.02
0.82
0.79
0.89
1.04
Age at first diagnosis 0–16 years 0.85
1.08
0.88
1.30
0.86
1.22
17–40 years 1.26
1.18
1.01
0.93
0.85
0.96
40 years1.01
1.24
0.95
0.83
0.89
1.00
CD location Ileal 0.91
1.13
0.88
Colonic 1.17
0.90
0.91
Ileocolonic 1.27
0.90
0.78
UC location Pancolitis 1.13
0.94
1.14
Left colon 1.24
0.73
0.92
Proctitis 1.27
1.00
0.93
CD Behavior Inflammatory 1.17
0.88
0.92
Stricturing 1.03
1.01
0.90
Penetrating 1.13
1.38
0.62
Ileal/stricturing 0.86
1.03
0.93
Colonic/inflammatory 1.24
0.84
0.93
Any relative with IBD 1.22
1.15
0.78
0.88
0.97
0.83
Bowel resection 0.93
1.10
1.09
0.79
0.77
1.29
Smoker at diagnosis 0.96
1.16
1.01
0.62
0.92
1.22
Ever used immunomodulators 1.08
1.43
1.07
1.16
0.82
0.88
Any EIMs 1.05
1.05
1.06
0.83
0.89
0.81